Drug Trial Radar · NCT06436781
Effect of Maolactin™ FMR on Exercise Recovery, Inflammation, and Muscle Comfort in an Otherwise Healthy Population
Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Sep 12, 2024
Primary completion
May 23, 2025
Study completion May 23, 2025
Sponsor
- Lead sponsor
- RDC Clinical Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- May 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a double blind, randomised, placebo-controlled, parallel-group trial to evaluate the effect of Maolactin FMR supplementation on post exercise inflammation, exercise recovery and muscle fatigue and pain in an otherwise healthy population of adults 18-65 years old over 10 weeks with 8 weeks of supplementation. This is PART A of the study.
Conditions
- Post Exercise Inflammation
- Exercise Recovery
- Muscle Fatigue
- Muscle Pain
Interventions
MaolactinDrug
Once daily dose of 2 capsules containing a total of 500mg/day Maolactin
MaltodextrinDrug
Once daily dose of 2 capsules of Maltodextrin containing a total of 0mg/day Maolactin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in post exercise muscle breakdownTime frame: Baseline (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise) and Week 8 (Pre-exercise and 0, 1, 2, 24 and 48 hours post exercise)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
RDC Clinical Pty Ltd
Brisbane, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.